References
  1. Gupta A, Madhavan MV, Sehgal K, et al. Extrapulmonary manifestations of COVID-19. Nat Med . 2020;26(7):1017-1032.
  2. Goldenberg NA, Sochet A, Albisetti M, et al. Consensus-based clinical recommendations and research priorities for anticoagulant thromboprophylaxis in children hospitalized for COVID-19-related illness. J ThrombHaemost . 2020;18(11):3099-3105.
  3. Loi M, Branchford B, Kim J, Self C, Nuss R. COVID-19 anticoagulation recommendations in children. Pediatr Blood Cancer . 2020;67(9):e28485.
  4. Mathuria JP, Yadav R, Rajkumar. Laboratory diagnosis of SARS-CoV-2 - A review of current methods. J Infect Public Health . 2020;13(7):901-905.
  5. Kotula JJ, Balakumar N, Khan D, Patel B. Bilateral pulmonary emboli in a teenager with positive SARS-CoV-2 antibody. PediatrPulmonol . 2021;56(1):271-273.
  6. Martinelli I, Ferrazzi E, Ciavarella A, et al. Pulmonary embolism in a young pregnant woman with COVID-19. Thromb Res . 2020;191:36-37.
  7. Hussain Z, Wangmo R, Gonbo S. Deep Vein Thrombosis After Trivial Blunt Trauma at High Altitude in a SARS-CoV-2 Positive Child: Complication of the Hypercoagulable State. Indian Pediatr . 2020;57(12):1182-1183.
  8. Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19.Thromb Res . 2020;191:145-147.
  9. Iba T, Levy JH, Levi M, Connors JM, Thachil J. Coagulopathy of Coronavirus Disease 2019. Crit Care Med . 2020;48(9):1358-1364.
  10. Middeldorp S, Coppens M, van Haaps TF, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J ThrombHaemost . 2020;18(8):1995-2002.
  11. Thachil J, Srivastava A. SARS-2 Coronavirus-Associated Hemostatic Lung Abnormality in COVID-19: Is It Pulmonary Thrombosis or Pulmonary Embolism?.Semin ThrombHemost . 2020;46(7):777-780.
  12. Branchford BR, Mahajerin A, Raffini L, et al. Recommendations for standardized risk factor definitions in pediatric hospital-acquired venous thromboembolism to inform future prevention trials: communication from the SSC of the ISTH. J Thromb Haemost . 2017;15(11):2274-2278.
  13. Wit JM, Hero M, Nunez SB. Aromatase inhibitors in pediatrics.Nat Rev Endocrinol . 2011;8(3):135-147.
  14. Baum M, Buzdar A, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer. 2003;98(9):1802-1810.
  15. Diaz-Thomas A, Shulman D. Use of aromatase inhibitors in children and adolescents: what’s new?. Curr Opin Pediatr.2010;22(4):501-507.
  16. Zhou B, She J, Wang Y, Ma X. Venous thrombosis and arteriosclerosis obliterans of lower extremities in a very severe patient with 2019 novel coronavirus disease: a case report. J Thromb Thrombolysis . 2020;50(1):229-232.
  17. Franch-Llasat D, Mayor-Vázquez E, Pedregosa-Díaz J, Herrero-Redondo M, Ortin-Font X, Roche-Campo F. e-Thrombosis in the COVID-19 era: collateral effects of confinement. Med Intensiva . 2020;S0210-5691(20)30265-5.
  18. Abou-Ismail MY, Diamond A, Kapoor S, Arafah Y, Nayak L. The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management. Thromb Res . 2020;194:101-115.
  19. Colling ME, Kanthi Y. COVID-19-associated coagulopathy: An exploration of mechanisms. Vasc Med . 2020;25(5):471-478.
  20. Jayarangaiah A, Kariyanna PT, Chen X, Jayarangaiah A, Kumar A. COVID-19-Associated Coagulopathy: An Exacerbated Immunothrombosis Response. Clin Appl ThrombHemost . 2020;26:1076029620943293.
  21. Pons S, Fodil S, Azoulay E, Zafrani L. The vascular endothelium: the cornerstone of organ dysfunction in severe SARS-CoV-2 infection.Crit Care. 2020;24(1):353.
  22. Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet . 2020;395(10234):1417-1418.
  23. Müller MM, Griesmacher A. Markers of endothelial dysfunction.Clin Chem Lab Med . 2000;38(2):77-85.
  24. Rauch A, Labreuche J, Lassalle F, Goutay J, Caplan M, Charbonnier L et al. Coagulation biomarkers are independent predictors of increased oxygen requirements in COVID-19. J Thromb Haemost . 2020;18(11):2942-53.
  25. Levi M, Iba T. COVID-19 coagulopathy: is it disseminated intravascular coagulation?. Intern Emerg Med . 2020;1-4.
  26. Iba T, Levy JH, Connors JM, Warkentin TE, Thachil J, Levi M. The unique characteristics of COVID-19 coagulopathy. Crit Care.2020;24(1):360.
  27. Gazzaruso C, Paolozzi E, Valenti C, et al. Association between antithrombin and mortality in patients with COVID-19. A possible link with obesity. Nutr Metab Cardiovasc Dis . 2020;30(11):1914-1919.
  28. Maldonado E, Tao D, Mackey K. Antithrombotic Therapies in COVID-19 Disease: a Systematic Review. J Gen Intern Med. 2020;35(9):2698-2706.
  29. Lippi G, Henry BM, Sanchis-Gomar F. Plasma Antithrombin Values Are Significantly Decreased in Coronavirus Disease 2019 (COVID-19) Patients with Severe Illness [published online ahead of print, 2020 Dec 30]. Semin Thromb Hemost . 2020;10.1055/s-0040-1716873.